CEBP http://www.cancermicroenvironment.tau.ac.il/welcome2009.html Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Epidemiology Biomarkers & Prevention 17, 255, January 1, 2008. doi: 10.1158/1055-9965.EPI-07-2588
© 2008 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deming, S. L.
Right arrow Articles by Zheng, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deming, S. L.
Right arrow Articles by Zheng, W.

Null Results in Brief

IGF-I and IGF-II Genetic Variation and Breast Cancer Risk in Chinese Women: Results from the Shanghai Breast Cancer Study

Sandra L. Deming1, Zefang Ren1, Qiuyin Cai1, Xiao-Ou Shu1, Wanqing Wen1, Ji-Rong Long1, Yu-Tang Gao2 and Wei Zheng1

1 Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tenessee and 2 Shanghai Cancer Institute, Shanghai, China

Requests for reprints: Wei Zheng, Institute for Medicine and Public Health, Vanderbilt University Medical Center, 8th Floor, Suite 800, 2525 West End Avenue, Nashville, TN 3720-1738. Phone: 615-936-0682; Fax: 615-936-8241. E-mail: wei.zheng{at}Vanderbilt.Edu


   Introduction
Top
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Insulin-like growth factor (IGF)-I and IGF-II have been implicated in breast tumorigenesis due to their ability to stimulate mitogenesis and promote differentiation and their key role in mammary gland cell proliferation and survival (1-3). It has been reported that genetic variations in the gene encoding IGF-I are associated with levels of the protein and, as a consequence, may alter breast cancer risk (4, 5). Results of recent studies investigating the role of IGF-I and IGF-II genetic polymorphisms in breast cancer risk have been inconsistent (4-10). The majority of the previous studies, including one from our own group, have focused on the (CA)n repeat in the promoter of the IGF-I gene (7-9, 11), whereas fewer have characterized common variants across the IGF-I and IGF-II genes in relationship to breast cancer susceptibility (4-6). To further assess the role of genetic variation in these genes, we evaluated the association between 23 single-nucleotide polymorphisms (SNP) in the IGF-I and IGF-II genes and breast cancer risk among participants of the Shanghai Breast Cancer Study, a population-based case-control study of incident breast cancer in urban Shanghai.


   Materials and Methods
Top
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Study Population
Detailed study methods have previously been published (12). Briefly, this study is a population-based case-control study of incident breast cancer in Chinese women in urban Shanghai, ages 25 to 64 years, who were recruited from 1996 to 1998. Of 1,602 eligible cases identified by the Shanghai Cancer Registry and 1,724 age-frequency matched controls identified using the Shanghai Resident Registry, 1,459 (91.1%) cases and 1,556 (90.3%) controls participated in the study. Approximately, 82% (1,193) of cases and 84% (1,310) of controls provided blood samples. Genomic DNA was extracted from buffy coats using the Puregene DNA Purification Kit (Gentra Systems) following the manufacturer's protocol. There were no differences in the distribution of demographic and risk factors between individuals who did and did not have DNA available for genotyping (13).

SNP Selection and Genotyping
To comprehensively evaluate the association between the IGF-I and IGF-II gene polymorphisms and breast cancer risk, we included haplotype tagging SNPs and potentially functional variants. Potentially functional and nonsynonymous SNPs were identified from literature reports and physical location (promoter or intron/exon boundary region) using the database SNPper3 or dbSNP.4 Haplotype tagging SNPs were identified from the Han Chinese data in the HapMap project for each gene plus flanking 5-kb region with the pairwise r2 ≥ 0.9 and minor allele frequency ≥0.05. The above-mentioned potentially functional SNPs were forced into the haplotype tagging SNP list. A total of 20 IGF-I and 3 IGF-II SNPs were included in the present study. The SNPs were genotyped by running the 5' nuclease TaqMan allelic discrimination assay (Applied Biosystems) and with the Affymetrix MegAllele Targeted Genotyping System (Affymetrix). The concordance rates for the quality control samples were 97% and 99% for TaqMan and Affymetrix methods, respectively.

Statistical Analysis
The {chi}2 test was used to compare the distributions of IGF-I and IGF-II alleles and genotypes in the cases and controls. The exact {chi}2 goodness-of-fit test was used to evaluate whether genotype distributions were in Hardy-Weinberg equilibrium. Odds ratios and 95% confidence intervals were estimated using logistic regression. All analyses were adjusted for age, with additional adjustment for other confounding factors including menopausal status, age at menarche, and age at first full-term pregnancy. Haplotypes were generated using the Haploview program (14), which uses an expectation-maximization algorithm to estimate haplotypes. Odds ratios and 95% confidence intervals for the association between haplotypes and breast cancer risk were generated using the Hapstat program (15). Associations between genotypes, haplotypes, and breast cancer risk were evaluated under additive, dominant, and recessive genetic models.


   Results
Top
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
The distributions of selected demographic characteristics and major risk factors for breast cancer among the cases and controls have been presented elsewhere (13). Briefly, the mean age was 47.7 ± 8.0 years among cases and 47.2 ± 8.7 years among controls. As compared with controls, cases were significantly more likely to have a history of fibroadenoma (9.8% versus 5.1%), a younger age at menarche (14.5 versus 14.7 years), an older age at menopause (48.2 versus 47.5 years), and a higher body mass index.

Table 1 details the polymorphisms in the IGF-I and IGF-II genes and their association with breast cancer risk. Genotype frequencies were comparable to those for the Chinese Han population included in HapMap. With the exception of one SNP (rs2288377), all genotype frequencies were found to be consistent with Hardy-Weinberg equilibrium among controls. None of the 23 polymorphisms we investigated were significantly associated with breast cancer risk when evaluated under additive, dominant, and recessive models. Haplotype blocks were estimated for both IGF-I and IGF-II genes, and no association between any of the haplotypes and altered breast cancer risk was observed. Table 2 presents results under the additive model. Findings were similar under dominant and recessive models (data not shown). Potential modifying effects by traditional risk factors were investigated on the relationship of the single polymorphisms and haplotypes with breast cancer risk. No evidence was found for an interaction between any of the genetic variants or haplotypes with age, menopausal status, body mass index, or waist-to-hip ratio (data not shown).


View this table:
[in this window]
[in a new window]

  		Table 1. Association between genetic polymorphisms in the IGF-I and IGF-II genes and breast cancer risk

 

View this table:
[in this window]
[in a new window]

  		Table 2. Association between IGF-I and IGF-II haplotypes and breast cancer risk

 

   Discussion
Top
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The results from this study suggest that common genetic variants in the IGF-I and IGF-II genes do not play a significant role in breast cancer risk among Chinese women. One of the main strengths of this study is its comprehensive and systematic approach to characterizing variation in IGF-I and IGF-II. We selected SNPs with known or potential function as well tagging SNPs to provide sufficient coverage across the gene. In addition, the large sample size provided sufficient power (≥80%) to detect a minimum odds ratio of ≥1.25 (assuming minor allele frequency ≥10%; {alpha} = 0.05 on the log-additive scale) and allowed evaluation of moderate or higher interactions between genetic polymorphisms and traditional breast cancer risk factors (16).

Although a number of studies have investigated the association between the (CA)n repeat polymorphism in the IGF-I promoter and breast cancer risk with inconsistent results (7-9, 11), only three evaluated the role of multiple common genetic variants across the IGF-I gene in breast cancer incidence (4-6). Our results are consistent with those observed among four other ethnic groups in a multiethnic cohort, which found no significant association between IGF-I variants or haplotypes and breast cancer risk (5). In an investigation of nine IGF-I polymorphisms, Al-Zahrani et al. (4) found that the variant allele in rs1520220 (a SNP not evaluated in our study but in high linkage disequilibrium with rs6220), although significantly related with reduced plasma IGF-I levels, was associated with an increased risk of breast cancer. This finding is unexpected given the tumor-promoting effects of IGF-I. Results from the European Prospective Investigation into Cancer and Nutrition study conducted primarily in the Caucasian population found a borderline significant association with breast cancer risk for the rs2162679 polymorphism in the IGF-I gene (odds ratio, 0.57; 95% confidence interval, 0.34-0.97 for the homozygous variant genotype) but not the four other SNPs investigated (rs35765, rs35767, rs6220, and rs6214). With respect to IGF-II, ours is the first study to evaluate polymorphisms across the gene in relation to breast cancer susceptibility.

Our results indicate that common genetic variants in the IGF-I or IGF-II genes may not appreciably alter breast cancer risk among Chinese women. However, we cannot rule out the possibility that some genetic variants may exert their effect through interactions with genetic polymorphisms in other genes or certain lifestyle factors. These interactions can be addressed in future studies with large sample size.


   Acknowledgments
 
We thank Qing Wang and Regina Courtney for their excellent technical laboratory assistance, Brandy Venuti for technical support in manuscript preparation, and all the study participants and research staff of the Shanghai Breast Cancer Study, who, through their support, made this study possible.


   Footnotes
 
Grant support: U.S. Public Health Service grants R01CA64277 and R01CA90899 from the National Cancer Institute.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Current address for Z. Ren: School of Public Health, Sun Yat-sen University, Guangzhou, China.

3 http://snpper.chip.org/bio/snpper-enter Back

4 http://www.ncbi.nlm.nih.gov/projects/SNP/ Back

Received 9/14/07; accepted 10/27/07.


   References
Top
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Deeks S, Richards J, Nandi S. Maintenance of normal rat mammary epithelial cells by insulin and insulin-like growth factor 1. Exp Cell Res 1988;174:448–60.[CrossRef][Medline]
  2. Shamay A, Cohen N, Niwa M, Gertler A. Effect of insulin-like growth factor I on deoxyribonucleic acid synthesis and galactopoiesis in bovine undifferentiated and lactating mammary tissue in vitro. Endocrinology 1988;123:804–9.[Abstract/Free Full Text]
  3. Pacher M, Seewald MJ, Mikula M, et al. Impact of constitutive IGF-I/IGF-II stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis 2007;28:49–59.[Abstract/Free Full Text]
  4. Al-Zahrani A, Sandhu MS, Luben RN, et al. IGF-I and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF-I, IGFBP3 and risk of breast cancer. Hum Mol Genet 2006;15:1–10.[Abstract/Free Full Text]
  5. Setiawan VW, Cheng I, Stram DO, et al. Igf-I genetic variation and breast cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2006;15:172–4.[Free Full Text]
  6. Canzian F, McKay JD, Cleveland RJ, et al. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 2006;94:299–307.[CrossRef][Medline]
  7. DeLellis K, Ingles S, Kolonel L, et al. IGF-I genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. Br J Cancer 2003;88:277–82.[CrossRef][Medline]
  8. Missmer SA, Haiman CA, Hunter DJ, et al. A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer 2002;100:332–6.[CrossRef][Medline]
  9. Wen W, Gao YT, Shu XO, et al. Insulin-like growth factor-I gene polymorphism and breast cancer risk in Chinese women. Int J Cancer 2005;113:307–11.[CrossRef][Medline]
  10. Cleveland RJ, Gammon MD, Edmiston SN, et al. IGF-I CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis 2006;27:758–65.[Abstract/Free Full Text]
  11. Yu H, Li BD, Smith M, Shi R, Berkel HJ, Kato I. Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Res Treat 2001;70:117–22.[CrossRef][Medline]
  12. Gao YT, Shu XO, Dai Q, et al. Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 2000;87:295–300.[CrossRef][Medline]
  13. Zheng W, Gao YT, Shu XO, et al. Population-based case-control study of CYP11A gene polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2004;13:709–14.[Abstract/Free Full Text]
  14. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263–5.[Abstract/Free Full Text]
  15. Lin DY, Zeng D, Millikan R. Maximum likelihood estimation of haplotype effects and haplotype-environment interactions in association studies. Genet Epidemiol 2005;29:299–312.[CrossRef][Medline]
  16. Gauderman W. Sample size requirement for case-control studies of gene environment interaction. Stat Med 2002;21:35–50.[CrossRef][Medline]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deming, S. L.
Right arrow Articles by Zheng, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deming, S. L.
Right arrow Articles by Zheng, W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online